GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Institutional Ownership

Eledon Pharmaceuticals (FRA:2TK) Institutional Ownership : 4.64% (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eledon Pharmaceuticals's institutional ownership is 4.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eledon Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eledon Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 83.58%.


Eledon Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Eledon Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Institutional Ownership Chart

Eledon Pharmaceuticals Historical Data

The historical data trend for Eledon Pharmaceuticals can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.13 7.31 5.41 5.27 5.19 7.38 7.38 7.20 7.20 4.64

Eledon Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines